Published in Blood on May 01, 2001
Immunological decision-making: how does the immune system decide to mount a helper T-cell response? Immunology (2007) 1.54
Serum antibodies to periodontal pathogens are a risk factor for Alzheimer's disease. Alzheimers Dement (2012) 1.28
Respiratory syncytial virus induces prostaglandin E2, IL-10 and IL-11 generation in antigen presenting cells. Clin Exp Immunol (2002) 1.25
In mice, tuberculosis progression is associated with intensive inflammatory response and the accumulation of Gr-1 cells in the lungs. PLoS One (2010) 1.13
Indoleamine 2,3-dioxygenase-expressing leukemic dendritic cells impair a leukemia-specific immune response by inducing potent T regulatory cells. Haematologica (2010) 0.96
Expression of CD62L on donor CD4(+) T cells in allografts: correlation with graft-versus-host disease after unmanipulated allogeneic blood and marrow transplantation. J Clin Immunol (2009) 0.78
Local overexpression of interleukin-11 in the central nervous system limits demyelination and enhances remyelination. Mediators Inflamm (2013) 0.77
The role of decidual cells in uterine hemostasis, menstruation, inflammation, adverse pregnancy outcomes and abnormal uterine bleeding. Hum Reprod Update (2016) 0.76
IL-11 in multiple sclerosis. Oncotarget (2015) 0.75
Cell-Intrinsic gp130 Signaling on CD4+ T Cells Shapes Long-Lasting Antiviral Immunity. J Immunol (2015) 0.75
The epidemiology of severe malaria in an area of low transmission in Thailand. Trans R Soc Trop Med Hyg (1997) 4.48
Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow Transplantation. N Engl J Med (1991) 4.17
Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood (1984) 3.65
European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol (2009) 3.56
Heterogeneity of tonsillar subepithelial B lymphocytes, the splenic marginal zone equivalents. J Immunol (2000) 3.13
Regulatory activity of autocrine IL-10 on dendritic cell functions. J Immunol (2001) 2.89
Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol (2007) 2.40
Antitumor vaccination: where we stand. Haematologica (2000) 2.30
IL-17 is produced by nickel-specific T lymphocytes and regulates ICAM-1 expression and chemokine production in human keratinocytes: synergistic or antagonist effects with IFN-gamma and TNF-alpha. J Immunol (1999) 2.29
Fractalkine (CX3CL1) as an amplification circuit of polarized Th1 responses. J Clin Invest (2001) 2.10
Guidelines for the use of recombinant human erythropoietin. Haematologica (1995) 1.94
Primary intestinal lymphoma: clinical and therapeutic features of 32 patients. Haematologica (1997) 1.88
Lower limb enthesopathy in patients with psoriasis without clinical signs of arthropathy: a hospital-based case-control study. Ann Rheum Dis (2007) 1.86
Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. J Clin Oncol (1995) 1.77
Interleukin-17 is produced by both Th1 and Th2 lymphocytes, and modulates interferon-gamma- and interleukin-4-induced activation of human keratinocytes. J Invest Dermatol (2000) 1.73
Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood (2001) 1.67
Vitamin D status in patients with chronic plaque psoriasis. Br J Dermatol (2012) 1.65
All-trans-retinoic acid and pseudotumor cerebri in a young adult with acute promyelocytic leukemia: a possible disease association. Haematologica (1996) 1.61
Safety of retroviral gene marking with a truncated NGF receptor. Nat Med (2003) 1.60
Merlin regulates transmembrane receptor accumulation and signaling at the plasma membrane in primary mouse Schwann cells and in human schwannomas. Oncogene (2008) 1.57
Indwelling ureteral stents and sexual health: a prospective, multivariate analysis. J Urol (2007) 1.55
Chemokine receptor expression and function in CD4+ T lymphocytes with regulatory activity. J Immunol (2001) 1.55
Anaplastic large-cell lymphoma: clinical and prognostic evaluation of 90 adult patients. J Clin Oncol (1996) 1.54
Low day 3 luteinizing hormone values are predictive of reduced response to ovarian stimulation. Hum Reprod (1998) 1.54
The role of positron emission tomography (PET) in the management of lymphoma patients. Ann Oncol (1999) 1.54
Ustekinumab does not increase body mass index in patients with chronic plaque psoriasis: a prospective cohort study. Br J Dermatol (2013) 1.53
Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients. J Antimicrob Chemother (1991) 1.49
Solitary plasmacytoma of bone and extramedullary plasmacytoma: two different entities? Ann Oncol (1995) 1.49
Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients. Ann Oncol (1998) 1.48
Study on Ki-67 immunoreactivity as a prognostic indicator in patients with advanced gastric cancer. Jpn J Clin Oncol (1998) 1.48
New insights in biology and current therapeutic options for patients with chronic myelogenous leukemia. Haematologica (1997) 1.47
Risk of second cancers in Waldenström macroglobulinemia. Ann Oncol (2011) 1.47
Dendritic cells as a major source of macrophage-derived chemokine/CCL22 in vitro and in vivo. Eur J Immunol (2001) 1.47
Ileo-rectal anastomosis in ulcerative colitis: results of a long-term follow-up study. Ital J Gastroenterol (1995) 1.43
An upper limit on the stochastic gravitational-wave background of cosmological origin. Nature (2009) 1.42
Porotic hyperostosis as a marker of health and nutritional conditions during childhood: studies at the transition between Imperial Rome and the Early Middle Ages. Am J Hum Biol (2001) 1.41
Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines. Leuk Res (2010) 1.40
A recently developed bifacial platelet-rich fibrin matrix. Eur Cell Mater (2010) 1.40
A prospective study of alpha-interferon and autologous bone marrow transplantation in chronic myeloid leukemia. The Italian Co-operative Study Group on Chronic Myeloid Leukemia. Haematologica (1999) 1.39
Ultrastructural phenotype of "intestinal-type" cells in columnar-lined esophagus. Ultrastruct Pathol (2002) 1.38
In situ staining of bromodeoxyuridine positive cells in normal and neoplastic colony-forming units grown on plasma clots. J Immunol Methods (1988) 1.38
Latent tuberculosis infection in patients with chronic plaque psoriasis who are candidates for biological therapy. Br J Dermatol (2014) 1.38
Extracellular ATP induces a distorted maturation of dendritic cells and inhibits their capacity to initiate Th1 responses. J Immunol (2001) 1.37
Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983--93 and 1994--8 at European Group for Blood and Marrow Transplantation centres. Br J Haematol (2001) 1.36
Leber's hereditary optic neuropathy: biochemical effect of 11778/ND4 and 3460/ND1 mutations and correlation with the mitochondrial genotype. Neurology (1997) 1.34
Nonsecretory multiple myeloma. Presenting findings, clinical course and prognosis. Acta Haematol (1985) 1.30
Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blasts. Leukemia (2007) 1.30
Interstitial granulomatous dermatitis: a distinct entity with characteristic histological and clinical pattern. Br J Dermatol (2012) 1.29
The Italian Consensus Conference on Diagnostic Criteria for Myelofibrosis with Myeloid Metaplasia. Br J Haematol (1999) 1.29
HLA-DR antigens on colonic epithelial cells in inflammatory bowel disease: I. Relation to the state of activation of lamina propria lymphocytes and to the epithelial expression of other surface markers. Clin Exp Immunol (1987) 1.28
Nongastrointestinal low-grade mucosa-associated lymphoid tissue lymphoma: analysis of 75 patients. J Clin Oncol (1999) 1.27
Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia. Leukemia (2011) 1.26
Peripheral T-cell lymphomas. Clinico-pathologic study of 168 cases diagnosed according to the R.E.A.L. Classification. Ann Oncol (1997) 1.26
Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells. Leukemia (2007) 1.20
The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF. Bone Marrow Transplant (2010) 1.19
Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma. J Clin Oncol (2000) 1.18
Human CD4+ T lymphocytes with remarkable regulatory functions on dendritic cells and nickel-specific Th1 immune responses. J Invest Dermatol (2000) 1.18
Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia. Leukemia (2012) 1.16
Ceramide inhibits antigen uptake and presentation by dendritic cells. J Exp Med (1996) 1.16
Salvage therapy with thalidomide in multiple myeloma patients relapsing after autologous peripheral blood stem cell transplantation. Haematologica (2001) 1.16
Staging and prognosis in chronic myelogenous leukemia. Semin Hematol (1988) 1.15
Increase in T gamma lymphocytes in B-cell chronic lymphocytic leukaemia. II. Correlation with clinical stage and findings in B-prolymphocytic leukaemia. Br J Haematol (1981) 1.15
Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study. J Eur Acad Dermatol Venereol (2007) 1.14
Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma. Blood (1997) 1.13
Prevalence of symptoms experienced by patients with different clinical types of psoriasis. Br J Dermatol (2004) 1.12
Emergency cholecystostomy and subsequent cholecystectomy for acute gallstone cholecystitis in the elderly. Br J Surg (1999) 1.11
Multicentre study on the prevalence of symptoms and symptomatic treatment in HIV infection. Central Italy PRESINT Group. J Palliat Care (1997) 1.11
Human dendritic cells very efficiently present a heterologous antigen expressed on the surface of recombinant gram-positive bacteria to CD4+ T lymphocytes. J Immunol (1999) 1.11
Keratinocytes from patients with atopic dermatitis and psoriasis show a distinct chemokine production profile in response to T cell-derived cytokines. J Allergy Clin Immunol (2001) 1.11
Protein architecture of avian reovirus S1133 and identification of the cell attachment protein. J Virol (1997) 1.11
Survival rate of antitumour necrosis factor-α treatments for psoriasis in routine dermatological practice: a multicentre observational study. Br J Dermatol (2013) 1.10
Molecular monitoring of minimal residual disease in patients in long-term complete remission after allogeneic stem cell transplantation for multiple myeloma. Blood (2000) 1.10
Cognitive and affective disorders associated to HIV infection in the HAART era: findings from the NeuroICONA study. Cognitive impairment and depression in HIV/AIDS. The NeuroICONA study. Acta Psychiatr Scand (2002) 1.09
Apoptosis induction with purine analogs on freshly isolated chronic myeloid leukemia cells. Haematologica (1995) 1.08
Primary mediastinal large B-cell lymphoma with sclerosis: a clinical study of 89 patients treated with MACOP-B chemotherapy and radiation therapy. Haematologica (2001) 1.08
Alteplase for hepatic veno-occlusive disease after bone-marrow transplantation. Lancet (1992) 1.08
High bcl-2 expression in acute myeloid leukemia cells correlates with CD34 positivity and complete remission rate. Leukemia (1997) 1.07
The P2 purinergic receptors of human dendritic cells: identification and coupling to cytokine release. FASEB J (2000) 1.06
Normal and neoplastic plasma cell membrane phenotype: studies with new monoclonal antibodies. Clin Exp Immunol (1987) 1.06
Functional alterations of the mitochondrially encoded ND4 subunit associated with Leber's hereditary optic neuropathy. FEBS Lett (1994) 1.05
Immortalized dendritic cell line fully competent in antigen presentation initiates primary T cell responses in vivo. J Exp Med (1993) 1.05
Plasma homocysteine and folate levels in patients with chronic plaque psoriasis. Br J Dermatol (2006) 1.05
Different cytokines regulate antigen uptake and presentation of a precursor dendritic cell line. Eur J Immunol (1996) 1.05
Virally mediated MafB transduction induces the monocyte commitment of human CD34+ hematopoietic stem/progenitor cells. Cell Death Differ (2006) 1.05
Oral therapeutic administration of a probiotic mixture suppresses established Th2 responses and systemic anaphylaxis in a murine model of food allergy. Allergy (2010) 1.04
Granulocyte macrophage colony-stimulating factor is overproduced by keratinocytes in atopic dermatitis. Implications for sustained dendritic cell activation in the skin. J Clin Invest (1997) 1.04
Incidence of primary and second cancers in renal transplant recipients: a multicenter cohort study. Am J Transplant (2012) 1.03
Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients. J Clin Oncol (2000) 1.03
Cross-resistance and imipenem. Lancet (1986) 1.02
Glycosaminoglycans delay the progression of nephropathy in NIDDM. Diabetes Care (1997) 1.02
AMP-dependent kinase/mammalian target of rapamycin complex 1 signaling in T-cell acute lymphoblastic leukemia: therapeutic implications. Leukemia (2011) 1.02